Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: GlobeNewswire
Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress. “2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO's Latest Insider Share Sale [Yahoo! Finance]Yahoo! Finance
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]Seeking Alpha
ARTV
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 144
- 12/12/25 - Form 4
- ARTV's page on the SEC website